GlassScriptPhysician profile
Kimberly Ha Bower
NPI 1245937960
$810.55
in general payments reported to CMS, 2019-2025
18 companies · $192 in 2025
The $192 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $380 · 2024: $239 · 2025: $192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $811.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $810.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $125.73 | 2023-2025 | Paragard T 380a, Paragard T 380a |
| Myriad Women'S Health, INC. | $114.06 | 2023 | Myrisk |
| Bayer Healthcare Pharmaceuticals INC. | $96.73 | 2023-2025 | |
| Organon LLC | $55.25 | 2023-2025 | Nexplanon |
| Biogen, INC. | $49.53 | 2025 | Zurzuvae |
| Baxter Healthcare | $47.57 | 2024 | Perclot |
| Abbvie INC. | $44.66 | 2023 | |
| Hologic Sales and Service, LLC | $36.35 | 2023-2025 | Myosure Tissue Removal Device, Novasure, Acessa Provu System |
| Astellas Pharma US INC | $33.19 | 2025 | Veozah |
| Exeltis, USA INC. | $31.98 | 2024-2025 | Slynd |
| Channel Medsystems, INC. | $28.23 | 2023 | |
| Shield Therapeutics INC | $27.06 | 2023 | Accrufer |
| Takeda Pharmaceuticals U.S.A., INC. | $23.54 | 2024 | Vpriv |
| Aspira Women'S Health INC | $23.36 | 2024 | Ova1 |
| Ethicon US, LLC | $21.65 | 2023 | Ethicon, Stratafix |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $20.36 | 2024 | Epclusa |
| Mayne Pharma Commercial LLC | $16.07 | 2023 | |
| Gynesonics, INC. | $15.23 | 2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Bower listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.